# Medications Development for Drug Abuse Disorders

> **NCT01188421** · PHASE1,PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 106 (actual)

## Conditions studied

- Opioid Related Disorders
- Opioid Dependence
- Opioid Addiction

## Interventions

- **DRUG:** Buprenorphine/naloxone
- **DRUG:** Clonidine
- **DRUG:** Tramadol ER

## Key facts

- **NCT ID:** NCT01188421
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2017-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188421, "Medications Development for Drug Abuse Disorders". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01188421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*